FOLR1 Antibody

1. This study demonstrated a new approach using a combination of EpCAM and FRalpha as CTC-capture targets to increase the sensitivity of CTC detection in NSCLC efficiently, specifically, and quickly. PMID:29352248
2. Several experimental studies in mice and human epidemiological and genetics studies have suggested that FOLR1 abnormalities are involved in a portion of human neural tube defects (NTD), although the solo defect of FOLR1 did not cause NTD. (Review) PMID:28244241
3. that FOLR1 is highly expressed in ovarian cancer but is reduced following multidrug resistance. FOLR1 may be a useful biomarker for ovarian cancer, and it may be useful as a therapeutic application to improve sensitivity to cisplatin treatment PMID:29433550
4. mTORC1 or mTORC2 silencing markedly decreases the plasma membrane expression of FR-alpha and RFC transporter isoforms without affecting global protein expression PMID:27562465
5. High Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer. PMID:28410844
6. The expression of folate receptor 1 (FOLR1) was significantly higher and occurred with higher frequency in metastatic lymph node samples from patients with advanced lung cancer. PMID:29110850
7. We identified eight novel variants in SLC19A1 and twelve novel variants in FOLR1, FOLR2, and FOLR3. Pathogenic variants include c.1265delG in SLC19A1 resulting in an early stop codon, four large insertion deletion variants in FOLR3, and a stop_gain variant in FOLR3 PMID:28948692
8. In this study, folate receptor alpha (FRa)-targeted nano-liposomes (FLP) were designed to enhance the anti-tumor effect by targeting delivery of exogenous PEDF gene to cervical cancer cells..These results clearly showed that FLP were desired carriers for PEDF gene and FLP/PEDF might represent a potential novel strategy for gene therapy of cervical cancer. PMID:27576898
9. Data show that higher folate receptor alpha (FRalpha) expression is predictive of a favorable prognosis in pancreatic ductal adenocarcinoma (PDAC) and FRalpha may represent a promising target for treatments. PMID:28430580
10. our results demonstrate the substantial therapeutic potential of novel 6-substituted pyrrolo[2,3-d]pyrimidine antifolates with dual targeting of PCFT and FRalpha toward Epithelial ovarian cancer that express a range of FRalpha, along with PCFT, as well as cisplatin resistance PMID:28138029
11. Low expression level of FOLR1 is associated with neuroendocrine lung tumors. PMID:27064343
12. FolR1 is a predictive candidate and a therapeutic target for medulloblastoma. PMID:28416738
13. Folr1 is a favorable target for fluorescence-guided surgery as tumor specific agent EC17 produced a clear fluorescent signal in ovarian and breast cancer tissue. PMID:27014973
14. The Folate receptor alpha is associated with the progression of cervical cancer and regulates cervical cancer cells growth through phosphorylating ERK1/2, c-Fos, and c-Jun, which are key factors of the ERK signaling pathway. PMID:28782518
15. Folate receptor alpha protein was expressed in the majority of lung adenocarcinomas and a minority of lung squamous cell carcinomas. Folate receptor alpha protein expression correlated with histologic grade for lung adenocarcinomas, and the greatest difference was observed between grade 1 and grade 3. PMID:26599808
16. The present study shows the efficacy of silencing HuR in lung cancer cells using folate-conjugated nanoparticle system that is directed towards folate receptor-alpha overexpressing cancer cells. PMID:27328938
17. This new protocol opens an effective way through synthesis and design of novel fluorescent nano-conjugates for FR expression investigation in tumor cells via targeted imaging, showing great potential in drug delivery mechanism study and cancer therapy PMID:26606305
18. Suppression of FOLR1 by RNA interference altered gene expression profile of taxol-resistant nasopharyngeal carcinoma cells. Apoptosis-related genes, gene alterations in viral carcinogenesis/MAPK pathways may be important for taxol resistance reversal. PMID:26617855
19. we confirmed the similarities between epithelial ovarian cancer and fallopian tube, normal and adenocarcinoma using FOLR1, FOLR2, CD68 and CD11b markers PMID:25971554
20. Suggest RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor-alpha. PMID:26359629
21. Folate receptor expression on murine and human adipose tissue macrophages PMID:26149693
22. Findings suggest the clinical development of IMGN853 as a novel targeted therapy for patients with folate receptor alpha (FRalpha)-expressing tumors. PMID:25904506
23. Suggest that FRalpha overexpression may play a role in the endometrioid endometrium carcinoma carcinogenesis and carcinoma progression from endometrial hyperplasia. PMID:26191275
24. triple negative/basal tumors were significantly associated with increased expression of FOLR1 mRNA, compared to ER+ and HER2+ tumors. PMID:25816016
25. Molecular dynamic simulation of the binding process of folic acid to folate receptor alpha PMID:25323390
26. Studies indicate folate receptor (FR) as a prognostic biomarker for ovarian cancer. PMID:25564455
27. The overexpression of folate receptor alpha mRNA was associated with growth of pituitary adenomas. PMID:26014017
28. this is the first study to simultaneously evaluate both DNA methylation and protein expression of all three folate transporter genes, FOLR1, PCFT, and RFC1, in colorectal cancer. PMID:25697897
29. FRalpha down-regulation might be capable of suppressing cervical cancer cell proliferation and promoting apoptosis. PMID:25081683
30. Survival times are improved in non-small-cell lung cancer patients whose tumors show strong membranous folate receptor alpha expression. PMID:24993594
31. the conditions associated with circulating FOLR1 protein in healthy individuals PMID:24810481
32. We concluded that quantitation of CTCs through FRalpha ligand-PCR could be a promising method for noninvasive diagnosis of bladder TCC. PMID:24771263
33. 74% of ER/PR-negative and 80% of triple-negative breast cancers expressed folate receptor alpha (FRA). The expression of FRA was significantly associated with a worse disease-free survival. PMID:24028341
34. Expression of FOLR1 is higher in pituitary adenomas of patients who are older than 50 years. PMID:23023342
35. FOLR1 was significantly elevated in the serum of ovarian cancer patients compared to serum of both healthy controls and patients with benign gynecological conditions. PMID:23528302
36. The FRalpha gene was expressed in all parathyroid cells analyzed, and the FRbeta gene was expressed by most. PMID:24206618
37. crystal structure of human FRalpha in complex with folic acid at 2.8 A resolution PMID:23851396
38. The data presented further support the hypothesis that folate receptor-alpha expression in gynecologic tumors is due to the cell of origin normally expressing this receptor PMID:23518909
39. EpCAM, FR-alpha, and VEGF-A are the most promising molecules for use in targeted intraoperative fluorescence imaging of endometriotic lesions owing to their favorable expression patterns and biomarker characteristics PMID:23332132
40. Studies indicate that folate receptor alpha (FOLR1), a folate transporter, is an attractive target for cancer therapy due to its high affinity for folate, restricted range of expression in normal tissue and differential over-expression in malignant tissue. PMID:23357463
41. Overexpression of folate receptor alpha was associated with ovarian tumor progression. PMID:23144806
42. The folate receptor alpha translocates to the nucleus, where it binds to cis-regulatory elements at promoter regions of Fgfr4 and Hes1, and regulates their expression. PMID:23243496
43. a large percentage of lung cancers, including squamous cell carcinomas in addition to adenocarcinomas, strongly express folate receptor alpha PMID:22984810
44. PCR analysis had confirmed the existence of FR-alpha, SMVT, and B ((0, +)) in Y-79 and ARPE-19 cells. PMID:22304562
45. High folate receptor alpha is associated with adenocarcinoma in non-small-cell lung carcinoma and and EGFR [corrected] mutation. PMID:22729036
46. alpha-FR can be a potential biomarker for the prediction of chemotherapeutic responses and clinical prognosis. PMID:22265591
47. studies suggest that different clinical severities do not necessarily correlate with residual function of folate receptor alpha mutants. PMID:22586289
48. FR-alpha was expressed in the majority of serous ovarian tumors, although >50% of cases showed only weak expression. PMID:21647742
49. FRalpha may play an important role in the development and progression of NFAs. PMID:22089756
50. An ancient double-mutated haplotype 1816delC-1841A in the FOLR1 gene, is demonstrated. PMID:21938430

Show More

Hide All

HGNC: 3791

UNIGENE: Hs.73769

KEGG: hsa:2348

STRING: 9606.ENSP00000308137

OMIM: 136430